Drug intelligence / Profile preview

LiteVax

Development stage: Unknown
Lead developer: LiteVax
Modality: Small Molecules
Administration: Intramuscular

Overview

LiteVax is a proprietary, synthetic carbohydrate-based vaccine adjuvant developed by the Dutch biotechnology company LiteVax B.V. Chemically, it is a sucrose fatty acid sulfate ester (SFASE) designed to enhance the immunogenicity of vaccines by stimulating both humoral (antibody) and cellular (T-cell) immune responses. LiteVax is formulated to be stable, safe, and easy to manufacture, and it is intended to improve vaccine efficacy in populations with weakened immune systems, such as older adults. It is currently being evaluated in clinical trials as a component of the TETRALITE program, which combines the LiteVax adjuvant with a quadrivalent influenza vaccine to provide superior protection against seasonal flu.

Brand names: LiteVax
Other names: SFASE adjuvantsucrose fatty acid sulfate ester adjuvant

Beyond the preview

Go deeper on LiteVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiteVax.

Explore the full profile